Table 1. Effect of imatinib on CRKL and... | American Society of Hematology

Table 1.

Effect of imatinib on CRKL and MAPK phosphorylation and CFC growth in individual CML patient samples

Sample	Phase	Prior imatinib at time of sampling	Response to imatinib treatment	P-CRKL	P-MAPK	CFC
1	CP	No	Did not receive	5	129	18
2	AP	No	NA	4	192	32
3	AP	No	Did not receive	35	165	39
4	CP	No	NA	0	50	46
5	CP	No	CCR	30	179	67
6	CP	Yes	Initial CHR followed by loss of response	79	219	106

Sample	Phase	Prior imatinib at time of sampling	Response to imatinib treatment	P-CRKL	P-MAPK	CFC
1	CP	No	Did not receive	5	129	18
2	AP	No	NA	4	192	32
3	AP	No	Did not receive	35	165	39
4	CP	No	NA	0	50	46
5	CP	No	CCR	30	179	67
6	CP	Yes	Initial CHR followed by loss of response	79	219	106

CML CD34⁺ cells were exposed to imatinib (1 mM) as described in “Patients, materials, and methods.” The effect of imatinib on P-CRKL, on P-MAPK, and on CFC growth in 6 individual CML patient samples is shown. Values shown are results for treated cells expressed as percentage of untreated controls.

CFC indicates colony-forming cells; NA, data not available; and CHR, complete hematologic remission.

View Large

This Feature Is Available To Subscribers Only